Amelioration of Colitis by a Gut Bacterial Consortium Producing Anti-Inflammatory Secondary Bile AcidsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether a designed consortium of gut bacteria could restore secondary bile acid metabolism and reduce intestinal inflammation. The researchers screened human gut bacterial strains for bile acid metabolizing activity and assembled a three-species consortium, named BAC, consisting of Clostridium AP sp000509125, Bacteroides ovatus, and Eubacterium limosum. They tested whether BAC could convert conjugated primary bile acids into the anti-inflammatory secondary bile acids ursodeoxycholic acid (UDCA) and lithocholic acid (LCA), both in vitro and in a mouse model of colitis.
Who was studied?
The subjects were mice given dextran sulfate sodium (DSS) to induce colitis, then treated with the BAC consortium by oral gavage. The bacterial strains themselves were sourced from the human gut, consistent with findings from the Integrative Human Microbiome Project and other human cohort studies on inflammatory bowel disease. No human patient cohort was directly enrolled or tested in this particular study.
What were the most important findings?
The BAC consortium converted taurochenodeoxycholic acid and glycochenodeoxycholic acid into the secondary bile acids UDCA and LCA in vitro. In DSS-treated mice, oral BAC treatment produced protective effects against colitis, including reduced weight loss and increased colon length. BAC treatment also raised fecal levels of bile acids, including UDCA and LCA, indicating that the consortium was functionally active in vivo.
What are the greatest implications of this study?
This study demonstrates that restoring secondary bile acid metabolism through a defined bacterial consortium can ameliorate colitis, directly addressing the bile acid dysbiosis seen in human inflammatory bowel disease. It suggests that engineered, function-based bacterial consortia, rather than single strains, may offer a targeted strategy for correcting metabolic deficits in dysbiotic guts. These findings support further investigation of bile acid-producing consortia such as BAC as a potential therapeutic approach for inflammatory bowel disease.